Search

Your search keyword '"Nitika"' showing total 27 results
Start Over Author "Nitika" Journal brachytherapy
27 results on '"Nitika"'

4. PHSOR09 Presentation Time: 1:10 PM

Author

Srivastava, Shiv, primary, Pinnaduwage, Dilini, additional, Ellefson, Steven, additional, Jani, Shyam, additional, Diaz, Aidnag, additional, Patel, Shyamal, additional, Sorensen, Stephen, additional, and Thawani, Nitika, additional

Published
2022
Full Text
View/download PDF

6. PO09

Author

Thawani, Nitika, primary, Jani, Shyam, additional, Kang, Bianca, additional, Yang, Min, additional, Sorenson, Stephen, additional, Srivastava, Shiv, additional, Pinnaduwage, Dilini, additional, Ellefson, Steven, additional, Diaz, Aidnag, additional, and Patel, Shyamal, additional

Published
2022
Full Text
View/download PDF

9. PO09

Author

Nitika Thawani, Shyam Jani, Bianca Kang, Min Yang, Stephen Sorenson, Shiv Srivastava, Dilini Pinnaduwage, Steven Ellefson, Aidnag Diaz, and Shyamal Patel

Subjects
Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

11. PHSOR09 Presentation Time: 1:10 PM

Author

Shiv Srivastava, Dilini Pinnaduwage, Steven Ellefson, Shyam Jani, Aidnag Diaz, Shyamal Patel, Stephen Sorensen, and Nitika Thawani

Subjects
Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

15. Gastrointestinal Brachytherapy

Author

Stewart, Alexandra J., primary, Tselis, Nikolaos, additional, Albert, Michele, additional, Thawani, Nitika, additional, and Myint, Arthur Sun, additional

Published
2015
Full Text
View/download PDF

27. Custom mold applicator high-dose-rate brachytherapy for nonmelanoma skin cancer—An analysis of 273 lesions.

Author

Jr.Olek, David, El-Ghamry, Moataz N., Deb, Niloyjyoti, Thawani, Nitika, Shaver, Courtney, and Mutyala, Subhakar

Subjects
*CANCER treatment, *SKIN cancer, *RADIOISOTOPE brachytherapy, *PUBLIC health, *CANCER relapse, *MEDICAL statistics
Abstract

Purpose Nonmelanoma skin cancer is the most commonly diagnosed malignancy in the United States. A modern version of surface brachytherapy, “topographic applicator brachytherapy” (TAB), can be used to treat early-stage nonmelanoma skin cancer (ES-NMSC). The purpose of this study was to evaluate the acute toxicity, chronic toxicity, and recurrence rates of patients with ES-NMSC treated with TAB. Methods and Materials From 2010 to 2013, 172 patients with 273 ES-NMSC tumors were consecutively treated with TAB. A custom applicator was created using a thermoplastic mold with Harrison Anderson Mick applicators. Dose fractionation schemes included 40 Gy in eight fractions delivered twice per week or 48 Gy in 16 fractions delivered four times per week. Results Of the 273 tumors treated, 23.8% were located on the nose, 54.2% were basal cell carcinoma, 76.2% were Stage I, 89.3% were treated definitively, 98.9% completed treatment, and 75.5% received 40 Gy in eight fractions. Median followup was 25.0 months (0.5–71.0 months). Maximum acute toxicity was G0, 0.4%; G1, 33.3%; G2, 48.7%; G3, 12.1%; and G4, 5.1%. Local recurrence was 4.8% at 25 months, with median time to recurrence being 9 months. There was no regional or distant metastasis documented during the followup. Chronic toxicities included erythema (4.4%), chronic ulceration (4.0%), telangiectasia (2.6%), and pigmentation changes (2.2%). Conclusions TAB was able to provide excellent local control (95.2%) with low rates of Grades 3 and 4 toxicities for treatment of ES-NMSC. TAB is a reasonable alternative to surgical resection when there is concern of poor cosmesis/wound healing. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results